Executive Team

Chaim Lebovits

Chief Executive Officer

Ralph Kern, MD, MHSc

President and Chief Medical Officer

David Setboun, PhD, MBA

EVP AND CHIEF OPERATING OFFICER

Stacy Lindborg, PhD

EVP and Head of Global Clinical Research

Preetam Shah, PhD, MBA

EVP and Chief Financial Officer

Arturo Araya, MBA

Chief Commercial Officer

Mary Kay Turner

VP Patient Advocacy and Government Affairs

Uri Yablonka

EVP and Chief Business Officer

Yael Gothelf, PhD

VP Scientific and Regulatory Affairs

Yossef Levy, PhD

VP Cell Production

Revital Aricha, PhD

VP Research & Development

Susan E. Ward, PhD

Head of Clinical Operations
Scroll to Top

Hi
Here you can see some frequently asked questions or contact us!

What passage are your cells?

Our human mesenchymal stem/stromal cells (hMSCs) are provided at a population doubling level (PDL) of 8-10 post-mononuclear isolation (Bone Marrow; Equivalent Passage 2) or 14-18 post-isolation from the perivascular region of Wharton’s Jelly (Umbilical Cord; Equivalent Passage 3). Due to variabilities of seeding and harvest densities we characterize our MSC “True Age” in terms of their PDL.

How often should I feed your cells?

A: There is no need to feed cells between passages. Our media is engineered to be a batch culture media, where no media exchange or feed is necessary when following our suggested protocols.

Are your vials sold from pooled donors?

No, we do not pool donors at any time during our production. Master Cell Banks (MCBs) are created from each donor source. Working Cell Banks (WCBs) are produced from our MCBs for general product sales.

What characterization do you provide for your hMSCs?

We characterize our hMSCs by following ISCT criteria: cell identity (surface marker expression), functional potency (angiogenic cytokine and IDO secretion), and trilineage differentiation (adipo-, osteo-, and chondrogenesis). This information is provided to allow customers to choose the optimal hMSC tissue type and donor for their specific application or target indication.